D. Roy Baynes's most recent trade in Natera Inc was a trade of 1,571 Common Stock done . Disclosure was reported to the exchange on June 26, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 1,571 | 20,083 (0%) | 0% | - | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 75 | 20,158 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.38 per share. | 12 Jun 2026 | 4,500 | 46,000 (0%) | 0% | 21.4 | 96,210 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2026 | 4,500 | 0 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 12 Jun 2026 | 4,500 | 41,500 (0%) | 0% | 50 | 225,000 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2026 | 12,000 | 12,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2026 | 4,000 | 41,500 (0%) | 0% | 0 | Common Stock | |
| Nurix Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2026 | 31,250 | 31,250 | - | - | Director Stock Option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 46.65 per share. | 05 May 2026 | 4,500 | 37,500 (0%) | 0% | 46.7 | 209,925 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.27 per share. | 05 May 2026 | 4,500 | 42,000 (0%) | 0% | 18.3 | 82,215 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2026 | 4,500 | 0 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.82 per share. | 01 May 2026 | 9,750 | 47,250 (0%) | 0% | 6.8 | 66,495 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 44.22 per share. | 01 May 2026 | 9,750 | 37,500 (0%) | 0% | 44.2 | 431,145 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2026 | 9,750 | 9,750 | - | - | Stock option (right to buy) | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2026 | 83 | 18,512 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 41.07 per share. | 14 Apr 2026 | 26,000 | 44,250 (0%) | 0% | 41.1 | 1,067,820 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2026 | 9,000 | 0 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.43 per share. | 14 Apr 2026 | 9,000 | 54,500 (0%) | 0% | 15.4 | 138,870 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2026 | 8,000 | 0 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.94 per share. | 14 Apr 2026 | 8,000 | 45,500 (0%) | 0% | 17.9 | 143,520 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2026 | 6,750 | 6,750 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 42.12 per share. | 14 Apr 2026 | 6,750 | 37,500 (0%) | 0% | 42.1 | 284,310 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.11 per share. | 14 Apr 2026 | 6,750 | 70,250 (0%) | 0% | 17.1 | 115,493 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.38 per share. | 14 Apr 2026 | 4,500 | 63,500 (0%) | 0% | 21.4 | 96,210 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.27 per share. | 14 Apr 2026 | 4,500 | 59,000 (0%) | 0% | 18.3 | 82,215 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2026 | 4,500 | 4,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2026 | 4,500 | 4,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.52 per share. | 06 Apr 2026 | 10,000 | 47,500 (0%) | 0% | 26.5 | 265,200 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 33.00 per share. | 06 Apr 2026 | 10,000 | 37,500 (0%) | 0% | 33 | 330,000 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2026 | 10,000 | 0 | - | - | Stock option (right to buy) | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2026 | 70 | 18,429 (0%) | 0% | - | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.19 per share. | 19 Nov 2025 | 7,068 | 26,027 (0%) | 0% | 41.2 | 291,131 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Nov 2025 | 7,068 | 0 | - | - | Stock Option (right to buy) | |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Nov 2025 | 5,112 | 600 | - | - | Stock Option (right to buy) | |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 40.93 per share. | 19 Nov 2025 | 5,112 | 23,471 (0%) | 0% | 40.9 | 209,234 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 216.07 per share. | 19 Nov 2025 | 2,135 | 18,359 (0%) | 0% | 216.1 | 461,304 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 223.90 per share. | 19 Nov 2025 | 1,900 | 20,243 (0%) | 0% | 223.9 | 425,417 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 224.89 per share. | 19 Nov 2025 | 1,884 | 18,359 (0%) | 0% | 224.9 | 423,685 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 222.90 per share. | 19 Nov 2025 | 1,800 | 22,143 (0%) | 0% | 222.9 | 401,220 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 214.79 per share. | 19 Nov 2025 | 1,727 | 20,494 (0%) | 0% | 214.8 | 370,946 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 213.47 per share. | 19 Nov 2025 | 1,250 | 22,221 (0%) | 0% | 213.5 | 266,839 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 220.14 per share. | 19 Nov 2025 | 1,184 | 24,843 (0%) | 0% | 220.1 | 260,646 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 221.81 per share. | 19 Nov 2025 | 900 | 23,943 (0%) | 0% | 221.8 | 199,632 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 40.93 per share. | 19 Nov 2025 | 600 | 18,959 (0%) | 0% | 40.9 | 24,558 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Nov 2025 | 600 | 0 | - | - | Stock Option (right to buy) | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2025 | 93 | 18,359 (0%) | 0% | - | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2025 | 108 | 18,266 (0%) | 0% | - | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2025 | 2,143 | 18,158 (0%) | 0% | - | Common Stock | |
| Aardvark Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 30,508 | 30,508 | - | - | Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 25,000 | 25,000 | - | - | Director Stock Option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 19,500 | 19,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 6,500 | 37,500 (0%) | 0% | 0 | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2025 | 116 | 16,015 (0%) | 0% | - | Common Stock | |
| Nurix Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2025 | 50,000 | 50,000 | - | - | Director Stock Option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.44 per share. | 06 Feb 2025 | 10,000 | 41,000 (0%) | 0% | 17.4 | 174,400 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 10,000 | 0 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 06 Feb 2025 | 10,000 | 31,000 (0%) | 0% | 22 | 220,000 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 92 | 15,899 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2025 | 16,000 | 0 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 23 Jan 2025 | 16,000 | 31,000 (0%) | 0% | 20 | 320,000 | Common Stock |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.50 per share. | 23 Jan 2025 | 16,000 | 47,000 (0%) | 0% | 17.5 | 280,000 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.83 per share. | 15 Nov 2024 | 22,000 | 37,807 (0%) | 0% | 22.8 | 502,260 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 22,000 | 0 | - | - | Stock Option (right to buy) | |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 145.21 per share. | 15 Nov 2024 | 16,404 | 31,133 (0%) | 0% | 145.2 | 2,381,997 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.42 per share. | 15 Nov 2024 | 15,230 | 53,037 (0%) | 0% | 24.4 | 371,917 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 15,230 | 0 | - | - | Stock Option (right to buy) | |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 147.31 per share. | 15 Nov 2024 | 9,467 | 19,896 (0%) | 0% | 147.3 | 1,394,620 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 144.26 per share. | 15 Nov 2024 | 5,500 | 47,537 (0%) | 0% | 144.3 | 793,419 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 148.74 per share. | 15 Nov 2024 | 2,106 | 17,790 (0%) | 0% | 148.7 | 313,250 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 149.98 per share. | 15 Nov 2024 | 1,983 | 15,807 (0%) | 0% | 150.0 | 297,408 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Sale of securities on an exchange or to another person at price $ 146.25 per share. | 15 Nov 2024 | 1,770 | 29,363 (0%) | 0% | 146.3 | 258,871 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Oct 2024 | 124 | 15,807 (0%) | 0% | - | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2024 | 143 | 15,683 (0%) | 0% | - | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2024 | 2,964 | 15,540 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 19,500 | 19,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 6,500 | 31,000 (0%) | 0% | 0 | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2024 | 169 | 12,576 (0%) | 0% | - | Common Stock | |
| Natera Inc | D. Roy Baynes | Director | Grant, award, or other acquisition of securities at price $ 63.79 per share. | 26 Jan 2024 | 215 | 12,407 (0%) | 0% | 63.8 | 13,715 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 48.48 per share. | 28 Jul 2023 | 264 | 11,870 (0%) | 0% | 48.5 | 12,799 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 4,255 | 4,255 | - | - | Stock Option (right to buy) | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 2,750 | 11,606 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 13,500 | 13,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 4,500 | 24,500 (0%) | 0% | 0 | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 54.73 per share. | 14 Apr 2023 | 228 | 5,322 (0%) | 0% | 54.7 | 12,478 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 40.01 per share. | 13 Jan 2023 | 312 | 5,094 (0%) | 0% | 40.0 | 12,483 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 45.42 per share. | 14 Oct 2022 | 275 | 4,782 (0%) | 0% | 45.4 | 12,491 | Common Stock |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2022 | 344 | 344 | - | - | Restricted Stock Unit | |
| Atara Biotherapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 31,500 | 31,500 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 20,500 | 43,500 (0%) | 0% | 0 | Common Stock | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2022 | 7,068 | 7,068 | - | - | Stock Option (right to buy) | |
| Natera Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2022 | 3,534 | 3,534 | - | - | Restricted Stock Unit | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 9,000 | 9,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Roy D. Baynes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 3,000 | 20,000 (0%) | 0% | 0 | Common Stock |